Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new drug application (NDA) for trastuzumab botidotin was accepted by China's National Medical Products Administration, a Tuesday bourse filing said.

The product is indicated for the treatment of adult patients with HER2 positive unresectable or metastatic breast cancer who have received at least one prior anti-HER2 therapy, according to the biopharmaceutical company.